Details for Patent: 7,976,870

✉ Email this page to a colleague

Which drugs does patent 7,976,870 protect, and when does it expire?

Patent 7,976,870 protects XARTEMIS XR and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 7,976,870

Title:	Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Abstract:	Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.
Inventor(s):	Berner; Bret (Half Moon Bay, CA), Louie-Helm; Jenny (Fremont, CA), Shell; John W. (Hillsborough, CA)
Assignee:	Depomed, Inc. (Menlo Park, CA)
Application Number:	10/769,574
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,976,870
Patent Claim Types: see list of patent claims	Use; Dosage form; Delivery; Formulation;

Drugs Protected by US Patent 7,976,870

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,976,870

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2409552	⤷ Sign Up
European Patent Office	1439826	⤷ Sign Up
Japan	2005507000	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.